Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H32O |
Molecular Weight | 300.4782 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCCC=C4CC[C@@]23[H]
InChI
InChIKey=ATXHVCQZZJYMCF-XUDSTZEESA-N
InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
DescriptionSources: https://www.drugbank.ca/drugs/DB01431
Sources: https://www.drugbank.ca/drugs/DB01431
Allylestrenol (INN) (brand names Gestanon, Gestanin, Orageston, Turinal, Gestin, others), or allyloestrenol (BAN), also known as 17α-allylestr-4-en-17β-ol or as 3-deketo-17α-allyl-19-nortestosterone, is a synthetic steroid with progestational activity, that is used to prevent threatened miscarriage, recurrent pregnancy loss, and premature labor. Allylestrenol has also been studied as a treatment for benign prostatic hyperplasia in men, with encouraging results. Although it is less potent as a progestogen relative to many other 19-nortestosterone derivatives, allylestrenol is said to be virtually devoid of androgenic, estrogenic, or glucocorticoid activity, and hence, unlike virtually all other 19-nortestosterone derivatives, appears to be a pure progestogen with similar effects to those of progesterone. Allylestrenol is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though notably not in the United States or Canada.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27121188 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Allynol Approved UseUnknown |
|||
Preventing | Allynol Approved UseUnknown |
|||
Preventing | Allynol Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH]. | 2002 May |
|
Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. | 2006 Jul |
|
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. | 2007 Jun 1 |
Patents
Sample Use Guides
Adult: PO- The recommended dose is 10 to 40 mg per day 1 week.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15316697
PC-3 cells were transfected with a DNA mixture containing pMMTV-luc reporter (1 lg), pSG5AR (960 ng), and pRL-TK (40 ng), and grown for 24 h. Then, 5 nM of DHT with/ without allylestrenol was added. The cells were incubated for another 24 h and luciferase activities were measured.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C776
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
||
|
WHO-ATC |
G03DC01
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
||
|
WHO-VATC |
QG03DC01
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
37723
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
SUB05339MIG
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
DTXSID9022574
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
432-60-0
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL2105618
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
100000087457
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
235905
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
D000500
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
125
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
525
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | RxNorm | ||
|
953
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
C80270
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
DB01431
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
I47VB5DZ8O
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
207-082-9
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
ALLYLESTRENOL
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | |||
|
m1552
Created by
admin on Fri Dec 15 15:12:38 UTC 2023 , Edited by admin on Fri Dec 15 15:12:38 UTC 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY